Ncet 2009, 374(9694):PubMed PMID: 19726078 ubMed PMID: 19726997. PubMed PMID: 19726078. 19. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S: Cardiovascular outcomes and mortality in sufferers working with clopidogrel with proton pump inhibitors immediately after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009, 120(23):2322329. PubMed PMID: 19933932. Pubmed Central PMCID: 2818789. Epub 2009/11/26. eng. 20. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Hall K, Daugherty JR, Kaltenbach LA, Stein CM: Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010, 152(6):33745. PubMed PMID: 20231564. Pubmed Central PMCID: 3176584. 21. Administration. UFaD: Facts for healthcare specialists: update for the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). U.S. Division of Overall health and Human Solutions. 11/17/2009. PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. 22. Juhasz M, Herszenyi L, Tulassay Z: Existing standings with the proton pump inhibitor and clopidogrel co-therapy: critique on an evolving field together with the eyes of the gastroenterologist. Digestion 2010, 81(1):105. PubMed PMID: 20029203. Epub 2009/12/24. eng. 23. Tsai YW, Wen YW, Huang WF, Chen PF, Kuo KN, Hsiao FY: Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with preceding gastrointestinal bleeding. J Gastroenterol 2011, 46(1):395. PubMed PMID: 20811753. 24. Hsu PI, Lai KH, Liu CP: Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in sufferers with atherosclerosis. Gastroenterology 2011, 140(three):79198. PubMed PMID: 21144850.Wang et al. BMC Pharmacology and Toxicology 2014, 15:22 http://www.Pipazethate Biological Activity biomedcentral/2050-6511/15/Page 8 of25.p,p’-DDE Autophagy Gaglia MA Jr, Torguson R, Hanna N, Gonzalez MA, Collins SD, Syed AI, Syed AI, Ben-Dor I, Maluenda G, Delhaye C, Wakabayashi K, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R: Relation of proton pump inhibitor use right after percutaneous coronary intervention with drug-eluting stents to outcomes.PMID:23319057 Am J Cardiol 2010, 105(six):83388. PubMed PMID: 20211327. 26. Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW: Partnership between cardiovascular outcomes and proton pump inhibitor use in individuals getting dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011, 20(10):1043049. PubMed PMID: 21823195. 27. Ahsberg K, Hoglund P, Stael von Holstein C: Mortality from peptic ulcer bleeding: the effect of comorbidity plus the use of drugs that promote bleeding. Aliment Pharmacol Therapeut Symp 2010, 32(six):80110. PubMed PMID: 20653635. 28. Jepsen P, Vilstrup H, Lash TL: Improvement and Validation of a Comorbidity Scoring Method for Individuals With Cirrhosis. Gastroenterology 2014, 146(1):14756. quiz e15-6. doi: ten.1053/j.gastro.2013.09.019. Epub 2013 Sep 18. PubMed PMID: 24055278. 29. Bratanic A, Puljiz Z, Ljubicicz N, Caric T, Jelicic I, Puljiz M, Puljiz M, Perko Z: Predictive elements of rebleeding and mortality following endoscopic hemostasis in bleeding peptic ulcers. Hepatogastroenterology 2013, 60 (121):11217. PubMed PMID: 22709912. 30. Lau JY, Barkun A,.